about
Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactionsA Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspectiveAbsorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Allopurinol pharmacogenetics: assessment of potential clinical usefulness.Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.Bioinformatics and variability in drug response: a protein structural perspective.Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response.Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms.The effects of obesity on drug pharmacokinetics in humans.The impact of next-generation sequencing on genomics.Pharmacogenomics and adverse drug reactions: the case of statins.A clinical perspective on ethical issues in genetic testing.DNA amplification techniques in pharmacogenomics.Pharmacogenetically driven treatments for alcoholism: are we there yet?Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.Minimum information required for a DMET experiment reporting.Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: where are we now? Where are we going?Defining baseline epigenetic landscapes in the rat liver.A Synopsis of the "Influence of Epigenetics, Genetics, and Immunology" Session Part A at the 35th Annual Society of Toxicologic Pathology Symposium.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.
P2860
Q26743858-AFD59DC5-7A3A-497F-9FFE-BEBB54B40610Q30235315-BF1B2C5E-9042-4E64-95BF-9B932759AE57Q33903573-9354C314-F32A-41FD-B66B-39CE9D8949F1Q34165511-6A4E5201-007B-4B5D-858A-6CCBA8F85805Q34236067-C7340CE6-F537-47E5-8C15-29D46FC0DC69Q35558084-5ACA1551-7C9B-4816-925D-EA42C2C27491Q35882638-A41A171D-C579-4DA9-BE7F-551604A28AB6Q36009999-E8D7214C-2B32-4921-B352-4FFAB3BC51C1Q36532363-8D493C2C-361A-453F-88B5-146181D21C83Q37813488-3C28A176-083D-4B1F-826A-6F473BEE391EQ37854751-72C5347C-2093-49FE-9AED-070D7ABE9B18Q37863302-552E8E78-22D9-440E-BC92-6BE1675FEEFAQ37875115-E50A0602-5B85-4267-84E7-804EE9E14CABQ37875810-520E53FB-DE3E-4512-B357-A65B80BEBD66Q37892534-743CB30A-2128-4556-BCB0-E99ABB44063EQ38010250-9FF67030-C3F0-4C31-9B6C-51F8074CFCCEQ38078188-2C1CC7D8-4CC3-4053-9BC3-5E57E88F522DQ38129733-58299FF9-6073-425D-ADF5-71788247E32FQ38407994-D83F1CD5-7675-4CA9-A4B4-6821F8F8A603Q38896107-7357937B-A24B-4285-866E-3351FDD9A295Q39742342-4C9C060A-66F4-47A7-B903-90328E12BA9FQ46262957-B50AC2CD-E968-4926-9838-D9A07485B2ABQ46474503-585DAD74-B3DF-4046-AD49-549BD5382749Q51760905-F9075044-82F2-48F2-96A5-CB59F848BB03
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetics and human genetic polymorphisms.
@en
Pharmacogenetics and human genetic polymorphisms.
@nl
type
label
Pharmacogenetics and human genetic polymorphisms.
@en
Pharmacogenetics and human genetic polymorphisms.
@nl
prefLabel
Pharmacogenetics and human genetic polymorphisms.
@en
Pharmacogenetics and human genetic polymorphisms.
@nl
P2860
P356
P1433
P1476
Pharmacogenetics and human genetic polymorphisms.
@en
P2093
Ann K Daly
P2860
P304
P356
10.1042/BJ20100522
P407
P577
2010-08-01T00:00:00Z